Kineta, Inc.

Website Links

Description

Mr. Philips oversees commercialization of Kineta’s drug programs including both internal initiatives as well as collaborative commercial alliances. He has over 25 years of pharmaceutical experience in the US and overseas with large, intermediate and start-up companies. His extensive career includes experience with development and commercialization of both small molecules and biologic agents in a variety of sectors including: oncology, autoimmune diseases, cardiovascular disorders, viral diseases, dermatology and others.

Bachelor's or master's degree in Immunology, Biochemistry, Cell Biology, or related field with at least five years of experience in biotechnology medical research. The candidate should have expertise in biochemical assays including ELISA, flow cytometry, immunofluorescent cytometry, and PCR. Must be computer proficient (Windows), possess excellent written and oral communication skills, show attention to detail, and have experience working in a fast-paced research environment.

Dr. Ernesto J. Muñoz is an Associate Director at Kineta Inc. where he is responsible for leading the company's Conopeptide-based neuropathic pain and inflammation treatment program. Dr. Muñoz also leads the in vivo drug efficacy studies and translational cellular immunology work for Kineta One’s autoimmune drug program. Dr. Muñoz has over fifteen years of research experience in the fields of immunology and infectious diseases with a focus on cellular and in vivo models of inflammation/autoimmunity and pathogenesis. Dr.

Kineta ® is a nationally-recognized biotechnology company focused on developing leading edge therapeutics in three large high need therapeutic areas: autoimmune disease, viral disease and chronic pain. Our company is focused on the development of novel drug candidates each the outcome of years of scientific exploration and supported by an extensive body of peer-reviewed NIH-supported research.

Kineta was founded in 2008 by Drs. Charles Magness and Shawn Iadonato and it is their third biotechnology company. They are longtime business partners and highly accomplished scientists with a proven track record as entrepreneurs. Previously they led Illumigen Biosciences and successfully developed a first-in-class antiviral therapeutic in addition to several other innovative programs. In 2007 Illumigen was sold to Cubist Pharmaceuticals (NASDAQ:CBST) in a preclinical deal valued at over $340M. Drs.

Fact sheet

Company contacts

Products & services

Similar companies nearby